List of Excipients in Branded Drug ELEPSIA XR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharma Advanced Research Company Limited	ELEPSIA XR	levetiracetam	47133-574	AMMONIA
Sun Pharma Advanced Research Company Limited	ELEPSIA XR	levetiracetam	47133-574	BUTYL ALCOHOL
Sun Pharma Advanced Research Company Limited	ELEPSIA XR	levetiracetam	47133-574	CELLULOSE, MICROCRYSTALLINE
Sun Pharma Advanced Research Company Limited	ELEPSIA XR	levetiracetam	47133-574	CROSPOVIDONE
Sun Pharma Advanced Research Company Limited	ELEPSIA XR	levetiracetam	47133-574	DIBUTYL SEBACATE
Sun Pharma Advanced Research Company Limited	ELEPSIA XR	levetiracetam	47133-574	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER

ELEPSIA XR Excipient Strategy and Commercial Opportunities

Last updated: October 1, 2026

Elepsia XR is an extended-release levetiracetam tablet marketed by Sun Pharmaceutical Industries for once-daily treatment of partial-onset seizures. Its commercial opportunity is driven less by active-ingredient exclusivity and more by controlled-release performance, manufacturing reliability, switching economics, and differentiated dosage strengths. The highest-value excipient strategy is a robust hydrophilic matrix or equivalent modified-release platform that reproduces the reference product’s dissolution profile while reducing tablet size, variability, and cost.

What is Elepsia XR and how does its formulation create commercial value?

Elepsia XR contains levetiracetam in an extended-release oral tablet. The product is designed for once-daily administration, unlike immediate-release levetiracetam products that are generally administered twice daily. FDA labeling identifies 500 mg and 750 mg extended-release strengths and instructs patients to swallow the tablets whole rather than crush, chew, or split them.[1]

The formulation value proposition has four components:

Commercial attribute	Elepsia XR implication
Active ingredient	Levetiracetam, a broad-use antiseizure medicine
Delivery system	Once-daily extended-release tablet
Primary formulation challenge	Maintaining controlled release across gastrointestinal conditions
Main differentiation opportunity	Lower-cost, stable, bioequivalent extended-release product or improved line extension

Levetiracetam is highly water soluble. That characteristic can create rapid drug release unless the formulation uses sufficient release-controlling polymer, tablet structure, coating, or another matrix-control mechanism. Excipient selection therefore has a direct effect on dissolution, dose dumping risk, tablet robustness, and regulatory comparability.

What excipients are used in Elepsia XR?

Public FDA labeling identifies inactive ingredients for Elepsia XR, including release-controlling and tableting excipients such as hypromellose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, polyethylene glycol, titanium dioxide, and colorants used in the film coating.[1]

The likely functional roles are:

Excipient class	Likely function in Elepsia XR
Hypromellose	Hydrophilic matrix formation and release control
Microcrystalline cellulose	Diluent, compressibility, tablet structure
Colloidal silicon dioxide	Glidant and powder-flow aid
Magnesium stearate	Lubricant
Polyethylene glycol	Film-coating plasticizer or coating component
Titanium dioxide and iron oxides	Opacification and color identification
Film-coating polymers	Tablet protection, swallowability, appearance, and product identification

Exact grade selection is commercially important. Hypromellose viscosity, particle-size distribution, substitution type, and hydration behavior can materially alter levetiracetam release. A formulation that uses the correct chemical excipient but the wrong grade can fail dissolution similarity or exhibit unacceptable batch-to-batch variability.

How should an excipient strategy reproduce the Elepsia XR release profile?

The preferred development strategy is a quality-by-design approach built around dissolution performance rather than a simple qualitative copy of the reference formula.

Matrix polymer strategy

Hypromellose is the most commercially practical starting point for an extended-release levetiracetam tablet. A high-viscosity grade can form a hydrated gel barrier that slows penetration of gastrointestinal fluid and controls diffusion and erosion.

Developers should screen:

• Hypromellose viscosity grades.
• Polymer concentration.
• Polymer particle size.
• Compression force.
• Tablet porosity.
• Drug-to-polymer ratio.
• Use of a second hydrophilic polymer.
• Granulation versus direct compression.

A high-polymer formulation may improve release control but increase tablet size and reduce manufacturability. A low-polymer formulation may improve swallowability but create an early-release spike.

Diluent and filler strategy

Microcrystalline cellulose is attractive because it supports direct compression and provides adequate mechanical strength at relatively low cost. However, its moisture sensitivity and compressibility can vary by grade. Mannitol, lactose, dibasic calcium phosphate, and starch-based fillers could provide alternative performance profiles, but each introduces formulation or regulatory tradeoffs.

Lactose may improve powder handling and tablet economics but can complicate excipient compatibility if the formulation includes reactive amines. Dibasic calcium phosphate can improve hardness and reduce hygroscopicity, but its density and insolubility may alter matrix hydration. Mannitol can improve mouthfeel but is less useful where tablet size and cost are primary constraints.

Lubricant optimization

Magnesium stearate is standard for manufacture, but excessive blending can reduce tablet wettability and delay or destabilize release. A formulation developer should treat lubricant concentration and blending time as critical process parameters. Sodium stearyl fumarate is a potential alternative where improved dissolution robustness or reduced hydrophobicity is needed.

Film-coating strategy

The film coat is unlikely to be the principal release-control mechanism if the product uses a matrix tablet. Its commercial value is still material. A durable, low-weight coating can reduce chipping, improve appearance, support strength-based differentiation, and facilitate supply-chain handling.

Film-coating colors also reduce dispensing errors between 500 mg and 750 mg strengths. A common coating system across strengths can lower inventory complexity.

What formulation patents protect Elepsia XR?

The strongest potential intellectual-property positions for an extended-release levetiracetam product generally relate to:

1. Controlled-release matrix composition.
2. Polymer concentration and viscosity grade.
3. Dissolution profile across multiple pH conditions.
4. Tablet geometry and compression parameters.
5. Manufacturing processes that reduce content variability.
6. Multiparticulate, osmotic, or coated-particle delivery systems.
7. Methods of achieving once-daily exposure.
8. Combination products or pediatric dosage forms.

Levetiracetam itself is an established active ingredient. Its basic composition-of-matter protection is no longer the principal barrier to entry. Commercial protection therefore depends on formulation, process, regulatory data, manufacturing know-how, trademarks, and market access.

A generic manufacturer may avoid infringement by using a different polymer system, a different release mechanism, or a different tablet architecture. That approach can reduce formulation-patent exposure but increases development risk because the alternative must still satisfy FDA bioequivalence and dissolution requirements.

What is the FDA regulatory status of Elepsia XR?

Elepsia XR is an FDA-approved extended-release levetiracetam product. The product is regulated as a prescription drug and is distinct from immediate-release levetiracetam tablets, oral solutions, and injectable products.[1]

For a competing product, the main U.S. regulatory routes are:

Route	Commercial use
ANDA under section 505(j)	Generic equivalent with the same active ingredient, dosage form, strength, route, and therapeutic equivalence target
505(b)(2) application	Reformulated or otherwise differentiated product relying partly on existing FDA findings
New drug application	Novel delivery system, combination, or clinically differentiated formulation

An ANDA applicant must establish pharmaceutical equivalence and bioequivalence. For an extended-release product, that assessment typically requires comparative pharmacokinetics and dissolution testing under multiple conditions. FDA guidance emphasizes the importance of evaluating modified-release products under fed and fasted conditions because food can alter drug release and systemic exposure.[2]

When does Elepsia XR lose exclusivity?

Elepsia XR’s commercial exclusivity is primarily affected by the expiry of formulation patents, regulatory exclusivity, and the availability of therapeutically equivalent products. Levetiracetam’s underlying active-ingredient protection is not the principal source of current exclusivity.

The relevant U.S. milestones are:

Exclusivity factor	Effect on Elepsia XR
New chemical entity exclusivity	Not a current barrier for an established active ingredient
Formulation patents	May delay or shape generic entry if listed and enforceable
Orange Book listings	Determine whether a generic applicant must certify against listed patents
Paragraph IV certification	Can trigger patent litigation and a potential 30-month stay
180-day generic exclusivity	Can affect the timing of subsequent ANDA competition
Pediatric exclusivity	Can add six months to qualifying listed protections, if applicable

The FDA Orange Book is the controlling public source for listed patents, exclusivity codes, therapeutic-equivalence ratings, and approved products.[3] Patent expiry must be assessed patent by patent because expiration dates can differ by patent term adjustment, patent-term extension, terminal disclaimers, and pediatric exclusivity.

What Paragraph IV challenges and patent litigation affect Elepsia XR?

A Paragraph IV challenge would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For an extended-release levetiracetam product, the principal litigation questions would likely concern:

• Whether the proposed generic practices a claimed release-control formulation.
• Whether the applicant’s dissolution profile falls within a patent claim.
• Whether a process claim covers the applicant’s granulation or compression method.
• Whether the listed patent is properly eligible for Orange Book listing.
• Whether the patent claims a clinically meaningful method of use.

A Paragraph IV filing can lead to patent litigation within 45 days of notice and may trigger a 30-month stay of approval under the Hatch-Waxman framework.[4] The commercial risk is highest where a formulation patent has broad composition claims and the reference product has limited design-around options.

A narrow process patent is less likely to block market entry if a generic manufacturer can use a different process. A broad matrix-composition patent presents a greater barrier because excipient substitution may not avoid the claim.

How strong is the Elepsia XR patent estate?

The patent estate should be viewed as moderate to weak at the active-ingredient level and potentially stronger at the formulation level.

Patent layer	Relative strength
Levetiracetam composition of matter	Low for current exclusivity purposes
Once-daily concept	Low to moderate, depending on claim scope
Specific matrix formulation	Moderate if claims are broad and technically supported
Narrow excipient ranges	Moderate to weak because of design-around options
Manufacturing process	Variable; often avoidable through alternate equipment or process conditions
Method of use	Usually limited where the indication is already established
Trademark and product identity	Commercially useful but not a generic-entry barrier

The practical strength of a patent estate depends on claim breadth, remaining term, validity history, prosecution statements, and whether a generic can achieve bioequivalence through a non-infringing formulation.

What commercial opportunities exist for Elepsia XR excipients?

Generic extended-release levetiracetam

The largest opportunity is supply of high-functionality excipients to generic manufacturers. Suppliers can compete through:

• Consistent hypromellose viscosity.
• Low-variability microcrystalline cellulose.
• Direct-compression excipient blends.
• Low-moisture excipient systems.
• Improved lubricant compatibility.
• Technical support for dissolution matching.

Excipient suppliers that provide formulation-development data can secure longer-term relationships than commodity suppliers selling only standard grades.

Co-processed excipient platforms

A co-processed matrix excipient could combine a release-controlling polymer, compressibility aid, and flow enhancer. The commercial benefit is lower development time and reduced process sensitivity. A platform designed for highly soluble drugs such as levetiracetam could be positioned for other extended-release products.

Pediatric and geriatric dosage forms

Elepsia XR is a swallowed tablet. A differentiated product could target patients who have difficulty swallowing through:

• Extended-release mini-tablets.
• Sprinkleable multiparticulates.
• Sachets containing coated granules.
• Orally dispersible systems with controlled-release particles.
• Lower-dose titration strengths.

These products may require a 505(b)(2) strategy rather than a conventional ANDA, particularly if the dosage form differs materially from the reference product.

Combination and adherence products

Levetiracetam could be incorporated into adherence-oriented packaging, calendar blister systems, or fixed-dose combinations where clinically justified. Packaging does not create core patent protection, but it can support payer contracts, pharmacy substitution programs, and patient-retention initiatives.

How does Elepsia XR compare with immediate-release levetiracetam?

Attribute	Elepsia XR	Immediate-release levetiracetam
Administration	Once daily	Usually twice daily
Primary benefit	Reduced dosing frequency	Broad dosage flexibility
Formulation complexity	High	Lower
Excipient importance	Critical to release control	Mainly tableting and stability
Generic development risk	Higher	Lower
Adherence positioning	Stronger	Weaker where dose burden matters
Pediatric flexibility	More limited as a tablet	Greater with oral solution and tablets

The extended-release segment can support a price premium only if the product maintains reliable supply, achieves payer coverage, and demonstrates a practical adherence advantage. Generic competition will narrow that premium, but modified-release manufacturing remains more technically demanding than immediate-release production.

What generic launch scenarios exist for Elepsia XR?

Three launch scenarios are commercially relevant:

1. A conventional ANDA entrant matches the reference dissolution and receives an AB therapeutic-equivalence rating. This is the highest-volume and lowest-price scenario.
2. A first-to-file Paragraph IV applicant obtains 180-day exclusivity or settles litigation with an authorized or branded competitor. This can produce a temporary pricing premium.
3. A differentiated 505(b)(2) product enters with a new dosage form, strength, or administration method. This requires greater development investment but may avoid direct tablet-to-tablet competition.

Manufacturing barriers include polymer-grade variability, scale-up effects, tablet hardness, dissolution drift, and fed-state pharmacokinetic differences. These barriers can delay launch even where patent risk is limited.

What are the key geographic and licensing opportunities?

The United States is the most structured market because Orange Book listings and Hatch-Waxman certifications define generic-entry pathways. Europe and other markets may offer opportunities through national or regional generic applications, but patent status, formulation protection, and reference-product requirements differ by jurisdiction.

Licensing opportunities include:

• Supply agreements for high-viscosity hypromellose.
• Co-development of direct-compression matrix platforms.
• Technology transfer for extended-release granulation.
• Regional commercialization of generic levetiracetam XR.
• Licensing of pediatric multiparticulate delivery systems.
• Contract manufacturing of controlled-release tablets.

A licensee should prioritize jurisdictions where the active ingredient is unprotected, regulatory substitution is established, and once-daily levetiracetam has meaningful payer or adherence value.

Key Takeaways

• Elepsia XR’s commercial value comes from once-daily modified release, not active-ingredient exclusivity.
• Hypromellose, microcrystalline cellulose, lubricant control, and coating performance are the central excipient considerations.
• The most attractive generic strategy is a robust matrix formulation that matches the reference dissolution profile without copying protected formulation claims.
• Pediatric, geriatric, sprinkleable, and multiparticulate products offer higher differentiation than another standard extended-release tablet.
• FDA Orange Book listings and Paragraph IV certifications determine the principal U.S. patent-entry risks.
• Excipient suppliers can capture value through low-variability grades, co-processed platforms, and formulation-development support.
• Manufacturing scale-up and fed-state bioequivalence are likely to be greater practical risks than the levetiracetam molecule itself.

FAQs

Is Elepsia XR an extended-release levetiracetam product?

Yes. Elepsia XR is a once-daily extended-release tablet containing levetiracetam, marketed in 500 mg and 750 mg strengths.[1]

Which excipient is most important for Elepsia XR release control?

Hypromellose is the principal release-control excipient identified in the product’s inactive-ingredient profile. Its viscosity grade and concentration can materially affect dissolution.

Can a generic manufacturer use different excipients from Elepsia XR?

Yes. A generic may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and dissolution performance.

Is a 505(b)(2) application suitable for a new Elepsia XR dosage form?

Potentially. A materially different dosage form, such as sprinkleable controlled-release granules or a pediatric multiparticulate product, may fit a 505(b)(2) strategy better than a conventional ANDA.

What is the main commercial risk for an Elepsia XR generic?

The main risks are failure to match the extended-release pharmacokinetic profile, dissolution variability during scale-up, food-effect differences, and patent litigation over formulation or manufacturing claims.

References

1. U.S. Food and Drug Administration. (n.d.). Elepsia XR prescribing information: Levetiracetam extended-release tablets.
2. U.S. Food and Drug Administration. (2009). Guidance for industry: Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.